Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRP-180 dose-ranging placebo-controlled phase 2 trial in type 1 narcolepsy
ACTRN12625000479404Phase 2Not yet recruiting
- Sponsor
- Bioron Pharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BRP-180 and bupropion in narcolepsy type 1 (NT1) (3 arms), sponsored by Bioron Pharma. Primary endpoint: Efficacy of chronic administration of low and high dose levels of BRP-180 on wakefulness in patients with narcolepsy. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
BRP-180bupropion
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on ACTRN12625000479404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000479404.